Global Next Generation Cancer Diagnostics Market

Next Generation Cancer Diagnostics Market Size, Share, Growth Analysis, By Application(Biomarker Development, CTC Analysis), By Cancer Type(Lung, Breast) - Industry Forecast 2024-2031

Report ID: SQMIG35A2226 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 67 | Figures: 77

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Analyst Support
$5,300
BUY NOW GET FREE SAMPLE

FAQs

Next Generation Cancer Diagnostics Market size was valued at USD 9.90 billion in 2022 and is poised to grow from USD 11.66 billion in 2023 to USD 43.25 billion by 2031, at a CAGR of 17.8% during the forecast period (2024-2031).

These companies are involved in the development, manufacturing, and commercialization of a range of next-generation cancer diagnostic technologies and tests, including liquid biopsies, NGS, and imaging techniques. The market is characterized by intense competition, with companies competing on the basis of product features, quality, pricing, and customer service. 'Abbott Laboratories', 'Agilent Technologies, Inc.', 'Bio-Rad Laboratories, Inc.', 'Danaher Corporation', 'Exact Sciences Corporation', 'F. Hoffmann-La Roche Ltd.', 'GE Healthcare', 'Grail, Inc.', 'Guardant Health, Inc.', 'Hologic, Inc.', 'Illumina, Inc.', 'Merck & Co., Inc.', 'Myriad Genetics, Inc.', 'NanoString Technologies, Inc.', 'Natera, Inc.', 'NeoGenomics, Inc.', 'Qiagen N.V.', 'Quest Diagnostics Incorporated', 'Siemens Healthineers AG', 'Sysmex Corporation', 'Thermo Fisher Scientific, Inc.', 'Veracyte, Inc.'

The rising demand for personalized medicines is another factor driving the growth of the next generation cancer diagnostics market. Personalized medicine involves tailoring treatments to individual patients based on their genetic profile and other characteristics. Next generation cancer diagnostics tools can help identify patients who are most likely to benefit from personalized treatments.

Liquid biopsy tests have emerged as a promising alternative to traditional tissue biopsy tests for cancer diagnosis and treatment monitoring. These tests involve the analysis of a patient's blood, urine, or other bodily fluids to detect cancer cells and other biomarkers. Liquid biopsy tests are less invasive and less expensive than traditional biopsy tests, and they can provide more frequent and accurate results. As a result, there has been a growing adoption of liquid biopsy tests in the market, with several companies investing in the development of these tests.

The largest market is expected to be in North America in 2021 and for the duration of the forecast. High per capita healthcare spending and supportive healthcare policies are responsible for the regional market expansion.

Related Reports

Dental Equipment Market
Buy Now GET FREE SAMPLE
Chemical Injection Skids Market
Buy Now GET FREE SAMPLE
Surgical Robotics Market
Buy Now GET FREE SAMPLE
Image-guided Therapy Systems Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Next Generation Cancer Diagnostics Market

Product ID: SQMIG35A2226

$5,300
BUY NOW GET FREE SAMPLE